title: Anti-angiogenic therapies in prostate cancer.
abstract: Prostate cancer (PCa) is the second most common type of cancer among men in Western societies. Once in the castrate-resistant metastatic setting therapeutic options are limited. The importance of angiogenesis in the progression of PCa has been widely reported providing a rationale to test anti-angiogenic compounds for PCa treatment in clinical trials (CTs). However, in spite of the promising results shown in preclinical models and some anti-tumor activity observed in CTs, to date, no angiogenic inhibitor has been approved for use in PCa. This editorial outlines the latest clinical evidence regarding anti-angiogenic therapies in PCa treatment.
authors.forename: José María
authors.initials: JM
authors.lastname: Martínez-Jabaloyas
authors.forename: José Antonio
authors.initials: JA
authors.lastname: March-Villalba
authors.forename: María Mercedes
authors.initials: MM
authors.lastname: Navarro-García
authors.forename: Francisco
authors.initials: F
authors.lastname: Dasi
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000098:blood supply / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors